{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:14:46Z","timestamp":1792502086703,"version":"4.5.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GR 1517\/27-1"],"award-info":[{"award-number":["GR 1517\/27-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The immunoproteasome (IP) is a specialized form of the 26S proteasome, in which the catalytic subunits \u03b21c, \u03b22c, and \u03b25c of the standard proteasome are replaced by LMP2, MECL-1, and LMP7. The IP is constitutively expressed in hematopoietic cells and its expression in non-hematopoietic cells can be induced by IFN-\u03b3. The IP plays a crucial role in different immune functions, including MHC class-I ligand generation, cytokine production, and T helper cell differentiation. Selective inhibition of the IP has shown therapeutic benefits in treating different autoimmune diseases in pre-clinical animal models. However, the effect of IP inhibition on antibody production in viral infection and vaccination has remained underexplored. In this study, we used ONX 0914, an LMP7\/LMP2-selective inhibitor of the IP, to study the effect of IP inhibition on B cells and antibody production. In vitro, continuous exposure to ONX 0914 in a human B cell lymphoma cell line and primary murine B and plasma cells led to poly-ubiquitinated protein accumulation, increased apoptosis, reduced antibody secretion, and impaired immunoglobulin class-switch. However, induction of virus neutralizing antibodies was not affected in IP inhibitor-treated mice. Furthermore, IP inhibition neither impaired vaccine-induced antibody responses, nor affected different B cell populations in two different vaccination models. These findings suggest that IP inhibition does not compromise vaccination efficacy and anti-viral humoral immunity, supporting the potential of IP-targeted therapies for autoimmune diseases.<\/jats:p>","DOI":"10.1038\/s41420-025-02818-w","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T17:29:25Z","timestamp":1764005365000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Immunoproteasome inhibition triggers protein stress and apoptosis in cells of B cell lineage without impairing vaccination-induced antibody responses"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0000-1885","authenticated-orcid":false,"given":"Dennis","family":"Mink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3280-448X","authenticated-orcid":false,"given":"Franziska","family":"Oliveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9697-1687","authenticated-orcid":false,"given":"Nazlim","family":"Kutsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Gonzalez Siebold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4143-3086","authenticated-orcid":false,"given":"Tony","family":"Muchamuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9428-2349","authenticated-orcid":false,"given":"Michael","family":"Basler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"2818_CR1","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1146\/annurev-biochem-062917-011931","volume":"87","author":"JAM Bard","year":"2018","unstructured":"Bard JAM, Goodall EA, Greene ER, Jonsson E, Dong KC, Martin A. Structure and function of the 26S proteasome. Annu Rev Biochem. 2018;87:697\u2013724.","journal-title":"Annu Rev Biochem"},{"key":"2818_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nri2687","volume":"10","author":"M Groettrup","year":"2010","unstructured":"Groettrup M, Kirk CJ, Basler M. Proteasomes in immune cells: more than peptide producers?. Nat Rev Immunol. 2010;10:73\u201378.","journal-title":"Nat Rev Immunol"},{"key":"2818_CR3","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1021\/cr0502504","volume":"107","author":"L Borissenko","year":"2007","unstructured":"Borissenko L, Groll M. 20S Proteasome and its inhibitors:\u2009crystallographic knowledge for drug development. Chem Rev. 2007;107:687\u2013717.","journal-title":"Chem Rev"},{"key":"2818_CR4","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.cell.2011.12.030","volume":"148","author":"EM Huber","year":"2012","unstructured":"Huber EM, Basler M, Schwab R, Heinemeyer W, Kirk CJ, Groettrup M, et al. Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity. Cell. 2012;148:727\u2013738.","journal-title":"Cell"},{"key":"2818_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1084\/jem.187.1.97","volume":"187","author":"TA Griffin","year":"1998","unstructured":"Griffin TA, Nandi D, Cruz M, Fehling HJ, Kaer LV, Monaco JJ, et al. Immunoproteasome assembly: cooperative incorporation of interferon \u03b3 (IFN-\u03b3)\u2013inducible subunits. J Exp Med. 1998;187:97\u2013104.","journal-title":"J Exp Med"},{"key":"2818_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/0014-5793(94)80612-8","volume":"343","author":"K Akiyama","year":"1994","unstructured":"Akiyama K, Kagawa S, Tamura T, Shimbara N, Takashina M, Kristensen P, et al. Replacement of proteasome subunits X and Y by LMP7 and LMP2 induced by interferon-\u03b3 for acquirement of the functional diversity responsible for antigen processing. FEBS Lett. 1994;343:85\u201388.","journal-title":"FEBS Lett"},{"key":"2818_CR7","doi-asserted-by":"crossref","unstructured":"Inholz K, Anderl JL, Klawitter M, Goebel H, Maurits E, Kirk CJ, et al. Proteasome composition in immune cells implies special immune-cell-specific immunoproteasome function. Eur J Immunol. 2024;54:e2350613.","DOI":"10.1002\/eji.202350613"},{"key":"2818_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06207-w","volume":"23","author":"X Wang","year":"2025","unstructured":"Wang X, You H, Zhang T, Li Y, Chen X, Basler M, et al. Immunoproteasome subunits are novel signatures for predicting efficacy of immunotherapy in muscle invasive bladder cancer. J Transl Med. 2025;23:228.","journal-title":"J Transl Med"},{"key":"2818_CR9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.coi.2012.11.004","volume":"25","author":"M Basler","year":"2013","unstructured":"Basler M, Kirk CJ, Groettrup M. The immunoproteasome in antigen processing and other immunological functions. Curr Opin Immunol. 2013;25:74\u201380.","journal-title":"Curr Opin Immunol"},{"key":"2818_CR10","doi-asserted-by":"publisher","first-page":"4182","DOI":"10.4049\/jimmunol.1201183","volume":"189","author":"KW Kalim","year":"2012","unstructured":"Kalim KW, Basler M, Kirk CJ, Groettrup M. Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation. J Immunol. 2012;189:4182\u20134193.","journal-title":"J Immunol"},{"key":"2818_CR11","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1002\/eji.201040620","volume":"40","author":"J Moebius","year":"2010","unstructured":"Moebius J, van den Broek M, Groettrup M, Basler M. Immunoproteasomes are essential for survival and expansion of T cells in virus-infected mice. Eur J Immunol. 2010;40:3439\u20133449.","journal-title":"Eur J Immunol"},{"key":"2818_CR12","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.3389\/fimmu.2018.02386","volume":"9","author":"C Schmidt","year":"2018","unstructured":"Schmidt C, Berger T, Groettrup M, Basler M. Immunoproteasome inhibition impairs T and B cell activation by restraining ERK signaling and proteostasis. Front Immunol. 2018;9:2386.","journal-title":"Front Immunol"},{"key":"2818_CR13","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/nm.1978","volume":"15","author":"T Muchamuel","year":"2009","unstructured":"Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, Lauer C, et al. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med. 2009;15:781\u2013787.","journal-title":"Nat Med"},{"key":"2818_CR14","doi-asserted-by":"crossref","unstructured":"Oliveri F, Mink D, Muchamuel T, Basler M. Immunoproteasome inhibition impairs differentiation but not survival of T helper 17 cells. Cells 2025;14:689.","DOI":"10.3390\/cells14100689"},{"key":"2818_CR15","doi-asserted-by":"publisher","first-page":"1075615","DOI":"10.3389\/fimmu.2022.1075615","volume":"13","author":"M Del Rio Oliva","year":"2022","unstructured":"Del Rio Oliva M, Mellett M, Basler M. Immunoproteasome inhibition attenuates experimental psoriasis. Front Immunol. 2022;13:1075615.","journal-title":"Front Immunol"},{"key":"2818_CR16","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/emmm.201303543","volume":"6","author":"M Basler","year":"2014","unstructured":"Basler M, Mundt S, Muchamuel T, Moll C, Jiang J, Groettrup M, et al. Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis. EMBO Mol Med. 2014;6:226\u2013238.","journal-title":"EMBO Mol Med"},{"key":"2818_CR17","doi-asserted-by":"publisher","first-page":"50447","DOI":"10.18632\/oncotarget.14579","volume":"8","author":"N Vachharajani","year":"2017","unstructured":"Vachharajani N, Joeris T, Luu M, Hartmann S, Pautz S, Jenike E, et al. Prevention of colitis-associated cancer by selective targeting of immunoproteasome subunit LMP7. Oncotarget. 2017;8:50447\u201350459.","journal-title":"Oncotarget"},{"key":"2818_CR18","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/cmi.2017.8","volume":"14","author":"F Xiao","year":"2017","unstructured":"Xiao F, Lin X, Tian J, Wang X, Chen Q, Rui K, et al. Proteasome inhibition suppresses Th17 cell generation and ameliorates autoimmune development in experimental Sj\u00f6gren\u2019s syndrome. Cell Mol Immunol. 2017;14:924\u2013934.","journal-title":"Cell Mol Immunol"},{"key":"2818_CR19","doi-asserted-by":"publisher","first-page":"870720","DOI":"10.3389\/fimmu.2022.870720","volume":"13","author":"F Oliveri","year":"2022","unstructured":"Oliveri F, Basler M, Rao TN, Fehling HJ, Groettrup M. immunoproteasome inhibition reduces the T helper 2 response in mouse models of allergic airway inflammation. Front Immunol. 2022;13:870720.","journal-title":"Front Immunol"},{"key":"2818_CR20","doi-asserted-by":"publisher","first-page":"2156091","DOI":"10.1080\/2162402X.2022.2156091","volume":"12","author":"J Koerner","year":"2023","unstructured":"Koerner J, Horvath D, Oliveri F, Li J, Basler M. Suppression of prostate cancer and amelioration of the immunosuppressive tumor microenvironment through selective immunoproteasome inhibition. Oncoimmunology. 2023;12:2156091.","journal-title":"Oncoimmunology"},{"key":"2818_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1043680","volume":"14","author":"T Muchamuel","year":"2023","unstructured":"Muchamuel T, Fan RA, Anderl JL, Bomba DJ, Johnson HWB, Lowe E, et al. Zetomipzomib (KZR-616) attenuates lupus in mice via modulation of innate and adaptive immune responses. Front Immunol. 2023;14:1043680.","journal-title":"Front Immunol"},{"key":"2818_CR22","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.3389\/fimmu.2019.02138","volume":"10","author":"DC Nguyen","year":"2019","unstructured":"Nguyen DC, Joyner CJ, Sanz I, Lee FE. factors affecting early antibody secreting cell maturation into long-lived plasma cells. Front Immunol. 2019;10:2138.","journal-title":"Front Immunol"},{"key":"2818_CR23","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/nri3795","volume":"15","author":"SL Nutt","year":"2015","unstructured":"Nutt SL, Hodgkin PD, Tarlinton DM, Corcoran LM. The generation of antibody-secreting plasma cells. Nat Rev Immunol. 2015;15:160\u2013171.","journal-title":"Nat Rev Immunol"},{"key":"2818_CR24","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jaci.2023.05.011","volume":"152","author":"P Satitsuksanoa","year":"2023","unstructured":"Satitsuksanoa P, Iwasaki S, Boersma J, Bel Imam M, Schneider SR, Chang I, et al. B cells: The many facets of B cells in allergic diseases. J Allergy Clin Immunol. 2023;152:567\u2013581.","journal-title":"J Allergy Clin Immunol"},{"key":"2818_CR25","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1146\/annurev.immunol.23.021704.115732","volume":"23","author":"LJ McHeyzer-Williams","year":"2005","unstructured":"McHeyzer-Williams LJ, McHeyzer-Williams MG. Antigen-specific memory B cell development. Annu Rev Immunol. 2005;23:487\u2013513.","journal-title":"Annu Rev Immunol"},{"key":"2818_CR26","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1006\/cimm.1993.1294","volume":"152","author":"V Brinkmann","year":"1993","unstructured":"Brinkmann V, Heusser CH. T cell-dependent differentiation of human B cells into IgM, IgG, IgA, or IgE plasma cells: high rate of antibody production by IgE plasma cells, but limited clonal expansion of IgE precursors. Cell Immunol. 1993;152:323\u2013332.","journal-title":"Cell Immunol"},{"key":"2818_CR27","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/j.seminhematol.2012.04.005","volume":"49","author":"S Cenci","year":"2012","unstructured":"Cenci S. The proteasome in terminal plasma cell differentiation. Semin Hematol. 2012;49:215\u2013222.","journal-title":"Semin Hematol"},{"key":"2818_CR28","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1600-6143.2008.02461.x","volume":"9","author":"DK Perry","year":"2009","unstructured":"Perry DK, Burns JM, Pollinger HS, Amiot BP, Gloor JM, Gores GJ, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant. 2009;9:201\u2013209.","journal-title":"Am J Transplant"},{"key":"2818_CR29","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1016\/j.febslet.2007.04.031","volume":"581","author":"S Cenci","year":"2007","unstructured":"Cenci S, Sitia R. Managing and exploiting stress in the antibody factory. FEBS Lett. 2007;581:3652\u20133657.","journal-title":"FEBS Lett"},{"key":"2818_CR30","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1182\/blood-2008-08-172734","volume":"113","author":"G Bianchi","year":"2009","unstructured":"Bianchi G, Oliva L, Cascio P, Pengo N, Fontana F, Cerruti F, et al. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood. 2009;113:3040\u20133049.","journal-title":"Blood"},{"key":"2818_CR31","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","volume":"107","author":"EA Obeng","year":"2006","unstructured":"Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr., Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006;107:4907\u20134916.","journal-title":"Blood"},{"key":"2818_CR32","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/nm1763","volume":"14","author":"K Neubert","year":"2008","unstructured":"Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med. 2008;14:748\u2013755.","journal-title":"Nat Med"},{"key":"2818_CR33","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2147\/tcrm.2006.2.3.271","volume":"2","author":"A Field-Smith","year":"2006","unstructured":"Field-Smith A, Morgan GJ, Davies FE. Bortezomib (velcadetrade mark) in the treatment of multiple myeloma. Ther Clin Risk Manag. 2006;2:271\u2013279.","journal-title":"Ther Clin Risk Manag"},{"key":"2818_CR34","doi-asserted-by":"publisher","DOI":"10.1177\/20406207211019612","volume":"12","author":"AJ Yee","year":"2021","unstructured":"Yee AJ. The role of carfilzomib in relapsed\/refractory multiple myeloma. Ther Adv Hematol. 2021;12:20406207211019612.","journal-title":"Ther Adv Hematol"},{"key":"2818_CR35","first-page":"S74","volume":"33","author":"M Basler","year":"2015","unstructured":"Basler M, Mundt S, Bitzer A, Schmidt C, Groettrup M. The immunoproteasome: a novel drug target for autoimmune diseases. Clin Exp Rheumatol. 2015;33:S74\u201379.","journal-title":"Clin Exp Rheumatol"},{"key":"2818_CR36","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/art.33333","volume":"64","author":"HT Ichikawa","year":"2012","unstructured":"Ichikawa HT, Conley T, Muchamuel T, Jiang J, Lee S, Owen T, et al. Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum. 2012;64:493\u2013503.","journal-title":"Arthritis Rheum"},{"key":"2818_CR37","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1093\/cvr\/cvac181","volume":"119","author":"J Li","year":"2022","unstructured":"Li J, Hu S, Johnson HWB, Kirk CJ, Xian P, Song Y, et al. Co-inhibition of immunoproteasome subunits LMP2 and LMP7 enables prevention of transplant arteriosclerosis. Cardiovas Res. 2022;119:1030\u20131045.","journal-title":"Cardiovas Res"},{"key":"2818_CR38","doi-asserted-by":"publisher","first-page":"8970","DOI":"10.1073\/pnas.94.17.8970","volume":"94","author":"M Groettrup","year":"1997","unstructured":"Groettrup M, Standera S, Stohwasser R, Kloetzel PM. The subunits MECL-1 and LMP2 are mutually required for incorporation into the 20S proteasome. Proc Natl Acad Sci USA. 1997;94:8970\u20138975.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2818_CR39","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-06-2258","volume":"67","author":"S Meister","year":"2007","unstructured":"Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 2007;67:1783\u20131792.","journal-title":"Cancer Res"},{"key":"2818_CR40","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1084\/jem.187.1.97","volume":"187","author":"TA Griffin","year":"1998","unstructured":"Griffin TA, Nandi D, Cruz M, Fehling HJ, Kaer LV, Monaco JJ, et al. Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits. J Exp Med. 1998;187:97\u2013104.","journal-title":"J Exp Med"},{"key":"2818_CR41","doi-asserted-by":"publisher","first-page":"6153","DOI":"10.1074\/jbc.M209292200","volume":"278","author":"M De","year":"2003","unstructured":"De M, Jayarapu K, Elenich L, Monaco JJ, Colbert RA, Griffin TA. Beta 2 subunit propeptides influence cooperative proteasome assembly. J Biol Chem. 2003;278:6153\u20136159.","journal-title":"J Biol Chem"},{"key":"2818_CR42","doi-asserted-by":"crossref","unstructured":"Horvath D, Basler M. PLGA particles in immunotherapy. Pharmaceutics 2023;15:615.","DOI":"10.3390\/pharmaceutics15020615"},{"key":"2818_CR43","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00251-018-1084-0","volume":"71","author":"M Basler","year":"2019","unstructured":"Basler M, Li J, Groettrup M. On the role of the immunoproteasome in transplant rejection. Immunogenetics. 2019;71:263\u2013271.","journal-title":"Immunogenetics"},{"key":"2818_CR44","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.kint.2017.09.023","volume":"93","author":"J Li","year":"2018","unstructured":"Li J, Basler M, Alvarez G, Brunner T, Kirk CJ, Groettrup M. Immunoproteasome inhibition prevents chronic antibody-mediated allograft rejection in renal transplantation. Kidney Int. 2018;93:670\u2013680.","journal-title":"Kidney Int"},{"key":"2818_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/frtra.2024.1494455","volume":"3","author":"AM Schwalb","year":"2024","unstructured":"Schwalb AM, Anwar I, DeLaura I, Ladowski JM, Yoon J, Belloni R, et al. Immunoproteasome inhibition reduces donor specific antibody production and cardiac allograft vasculopathy in a mouse heart transplantation model. Front Transpl. 2024;3:1494455.","journal-title":"Front Transpl"},{"key":"2818_CR46","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.kint.2018.10.022","volume":"95","author":"J Li","year":"2019","unstructured":"Li J, Koerner J, Basler M, Brunner T, Kirk CJ, Groettrup M. Immunoproteasome inhibition induces plasma cell apoptosis and preserves kidney allografts by activating the unfolded protein response and suppressing plasma cell survival factors. Kidney Int. 2019;95:611\u2013623.","journal-title":"Kidney Int"},{"key":"2818_CR47","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1136\/annrheumdis-2020-eular.2700","volume":"79","author":"R Furie","year":"2020","unstructured":"Furie R, Parikh S, Maiquez A, Khan A, Moreno O, Soneira M, et al. AB0373 Treatment of SLE with the immunoproteasome inhibitor KZR-616: Results from the first 4 cohorts of the mission study, an open-label phase 1B dose escalation trial. Ann Rheum Dis. 2020;79:1486\u20131487.","journal-title":"Ann Rheum Dis"},{"key":"2818_CR48","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1146\/annurev.biochem.73.011303.074134","volume":"74","author":"M Schr\u00f6der","year":"2005","unstructured":"Schr\u00f6der M, Kaufman RJ. The mammalian unfolded protein response. Annu Rev Biochem. 2005;74:739\u2013789.","journal-title":"Annu Rev Biochem"},{"key":"2818_CR49","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/sj.embor.7400779","volume":"7","author":"E Szegezdi","year":"2006","unstructured":"Szegezdi E, Logue SE, Gorman AM, Samali A. Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep. 2006;7:880\u2013885.","journal-title":"EMBO Rep"},{"key":"2818_CR50","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/bph.14069","volume":"175","author":"M Basler","year":"2018","unstructured":"Basler M, Maurits E, de Bruin G, Koerner J, Overkleeft HS, Groettrup M. Amelioration of autoimmunity with an inhibitor selectively targeting all active centres of the immunoproteasome. Br J Pharm. 2018;175:38\u201352.","journal-title":"Br J Pharm"},{"key":"2818_CR51","first-page":"3071","volume":"61","author":"T Hideshima","year":"2001","unstructured":"Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071\u20133076.","journal-title":"Cancer Res"},{"key":"2818_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1184982","volume":"10","author":"HB Figueiredo Galvao","year":"2023","unstructured":"Figueiredo Galvao HB, Dinh QN, Thomas JM, Wassef F, Diep H, Bobik A, et al. Proteasome inhibition reduces plasma cell and antibody secretion, but not angiotensin II-induced hypertension. Front Cardiovasc Med. 2023;10:1184982.","journal-title":"Front Cardiovasc Med"},{"key":"2818_CR53","doi-asserted-by":"crossref","unstructured":"Matthews AJ, Zheng S, DiMenna LJ, Chaudhuri J. Advances in immunology 122 In: Frederick W, editor. Academic Press; 2014. 1\u201357.","DOI":"10.1016\/B978-0-12-800267-4.00001-8"},{"key":"2818_CR54","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S0092-8674(00)00078-7","volume":"102","author":"M Muramatsu","year":"2000","unstructured":"Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell. 2000;102:553\u2013563.","journal-title":"Cell"},{"key":"2818_CR55","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0092-8674(00)00079-9","volume":"102","author":"P Revy","year":"2000","unstructured":"Revy P, Muto T, Levy Y, Geissmann F, Plebani A, Sanal O, et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell. 2000;102:565\u2013575.","journal-title":"Cell"},{"key":"2818_CR56","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.molcel.2017.06.034","volume":"67","author":"Q Qiao","year":"2017","unstructured":"Qiao Q, Wang L, Meng F-L, Hwang JK, Alt FW, Wu H. AID recognizes structured DNA for class switch recombination. Mol Cell. 2017;67:361\u2013373.e364.","journal-title":"Mol Cell"},{"key":"2818_CR57","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3109\/08916934.2012.749244","volume":"46","author":"H Zan","year":"2013","unstructured":"Zan H, Casali P. Regulation of Aicda expression and AID activity. Autoimmunity. 2013;46:83\u2013101.","journal-title":"Autoimmunity"},{"key":"2818_CR58","doi-asserted-by":"publisher","first-page":"5587","DOI":"10.1038\/sj.onc.1210344","volume":"26","author":"Y Endo","year":"2007","unstructured":"Endo Y, Marusawa H, Kinoshita K, Morisawa T, Sakurai T, Okazaki IM, et al. Expression of activation-induced cytidine deaminase in human hepatocytes via NF-kappaB signaling. Oncogene. 2007;26:5587\u20135595.","journal-title":"Oncogene"},{"key":"2818_CR59","doi-asserted-by":"publisher","first-page":"5433","DOI":"10.1002\/j.1460-2075.1994.tb06878.x","volume":"13","author":"EB Traenckner","year":"1994","unstructured":"Traenckner EB, Wilk S, Baeuerle PA. A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B. EMBO J. 1994;13:5433\u20135441.","journal-title":"EMBO J"},{"key":"2818_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01433-5","volume":"22","author":"M Pakjoo","year":"2024","unstructured":"Pakjoo M, Ahmadi SE, Zahedi M, Jaafari N, Khademi R, Amini A, et al. Interplay between proteasome inhibitors and NF-\u03baB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors. Cell Commun Signal. 2024;22:105.","journal-title":"Cell Commun Signal"},{"key":"2818_CR61","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S0092-8674(94)90482-0","volume":"78","author":"VJ Palombella","year":"1994","unstructured":"Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitinproteasome pathway is required for processing the NF-\u03baB1 precursor protein and the activation of NF-\u03baB. Cell. 1994;78:773\u2013785.","journal-title":"Cell"},{"key":"2818_CR62","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.molimm.2017.01.019","volume":"83","author":"A Bitzer","year":"2017","unstructured":"Bitzer A, Basler M, Krappmann D, Groettrup M. Immunoproteasome subunit deficiency has no influence on the canonical pathway of NF-\u03baB activation. Mol Immunol. 2017;83:147\u2013153.","journal-title":"Mol Immunol"},{"key":"2818_CR63","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S1074-7613(02)00425-9","volume":"17","author":"N Kayagaki","year":"2002","unstructured":"Kayagaki N, Yan M, Seshasayee D, Wang H, Lee W, French DM, et al. BAFF\/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-\u03baB2. Immunity. 2002;17:515\u2013524.","journal-title":"Immunity"},{"key":"2818_CR64","doi-asserted-by":"publisher","first-page":"788","DOI":"10.3389\/fimmu.2019.00788","volume":"10","author":"RL Lindquist","year":"2019","unstructured":"Lindquist RL, Niesner RA, Hauser AE. In the right place, at the right time: spatiotemporal conditions determining plasma cell survival and function. Front Immunol. 2019;10:788.","journal-title":"Front Immunol"},{"key":"2818_CR65","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41435-020-00109-1","volume":"21","author":"M Basler","year":"2020","unstructured":"Basler M, Groettrup M. Recent insights how combined inhibition of immuno\/proteasome subunits enables therapeutic efficacy. Genes Immun. 2020;21:273\u2013287.","journal-title":"Genes Immun"},{"key":"2818_CR66","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ejim.2011.02.006","volume":"22","author":"DC Matthews","year":"2011","unstructured":"Matthews DC, Syed AA. The role of TSH receptor antibodies in the management of Graves\u2019 disease. Eur J Intern Med. 2011;22:213\u2013216.","journal-title":"Eur J Intern Med"},{"key":"2818_CR67","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1365-2249.2012.04578.x","volume":"168","author":"Y Nagayama","year":"2012","unstructured":"Nagayama Y, Nakahara M, Shimamura M, Horie I, Arima K, Abiru N. Prophylactic and therapeutic efficacies of a selective inhibitor of the immunoproteasome for Hashimoto\u2019s thyroiditis, but not for Graves\u2019 hyperthyroidism, in mice. Clin Exp Immunol. 2012;168:268\u2013273.","journal-title":"Clin Exp Immunol"},{"key":"2818_CR68","doi-asserted-by":"crossref","unstructured":"Wang J, Fang Y, Fan RA, Kirk CJ. Proteasome inhibitors and their pharmacokinetics, pharmacodynamics, and metabolism. Int J Mol Sci. 2021;22:11595.","DOI":"10.3390\/ijms222111595"},{"key":"2818_CR69","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1126\/science.8066463","volume":"265","author":"HJ Fehling","year":"1994","unstructured":"Fehling HJ, Swat W, Laplace C, K\u00fchn R, Rajewsky K, M\u00fcller U, et al. MHC class I expression in mice lacking the proteasome subunit LMP-7. Science. 1994;265:1234\u20131237.","journal-title":"Science"},{"key":"2818_CR70","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1073\/pnas.90.5.1657","volume":"90","author":"S Braselmann","year":"1993","unstructured":"Braselmann S, Graninger P, Busslinger M. A selective transcriptional induction system for mammalian cells based on Gal4-estrogen receptor fusion proteins. Proc Natl Acad Sci USA. 1993;90:1657\u20131661.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2818_CR71","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/978-1-61779-474-2_27","volume":"832","author":"M Basler","year":"2012","unstructured":"Basler M, Groettrup M. Immunoproteasome-specific inhibitors and their application. Methods Mol Biol. 2012;832:391\u2013401.","journal-title":"Methods Mol Biol"},{"key":"2818_CR72","doi-asserted-by":"publisher","first-page":"6665","DOI":"10.4049\/jimmunol.176.11.6665","volume":"176","author":"M Basler","year":"2006","unstructured":"Basler M, Moebius J, Elenich L, Groettrup M, Monaco JJ. An altered T cell repertoire in MECL-1-deficient mice. J Immunol. 2006;176:6665\u20136672.","journal-title":"J Immunol"},{"key":"2818_CR73","doi-asserted-by":"crossref","unstructured":"Basler M, Lindstrom MM, LaStant JJ, Bradshaw JM, Owens TD, Schmidt C, et al. Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity. EMBO Rep. 2018;19:e46512.","DOI":"10.15252\/embr.201846512"},{"key":"2818_CR74","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.4049\/jimmunol.1900182","volume":"203","author":"M Basler","year":"2019","unstructured":"Basler M, Claus M, Klawitter M, Goebel H, Groettrup M. Immunoproteasome inhibition selectively kills human CD14+ monocytes and as a result dampens IL-23 secretion. J Immunol. 2019;203:1776\u20131785.","journal-title":"J Immunol"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02818-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02818-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02818-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:02:26Z","timestamp":1781715746000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02818-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2818"],"URL":"https:\/\/doi.org\/10.1038\/s41420-025-02818-w","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TM is employed by and is shareholder of Kezar Life Sciences. This study was partially funded by research support from Kezar Life Sciences. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Animal experiments have been conducted in compliance with ethical standards of German and EU guidelines after approval by the animal experimentation ethics committee of the Review Board of the Governmental Presidium Freiburg, Germany with the approval numbers T-21\/03TFA, T-24\/02TFA, G-23\/059 or the Ethics Committee of Chongqing University Cancer Hospital (CZLS2020289-A).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"545"}}